Search

Your search keyword '"Reindl, Markus"' showing total 1,058 results

Search Constraints

Start Over You searched for: Author "Reindl, Markus" Remove constraint Author: "Reindl, Markus"
1,058 results on '"Reindl, Markus"'

Search Results

101. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association

102. Complement Activation Is a Prominent Feature ofMOGAD

104. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients

107. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases

110. sj-pdf-1-mso-10.1177_20552173211022767 - Supplemental material for Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients

112. Additional file 1 of Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?

116. Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study

117. NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders

118. MOG-Abs in CSF only: pathological findings support the diagnostic role (4181)

121. Replication study of multiple sclerosis (MS) susceptibility alleles and correlation of DNA-variants with disease features in a cohort of Austrian MS patients

124. Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis

127. 6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort

129. Additional file 1 of Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes

130. Additional file 7 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients

131. Additional file 1 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients

132. Additional file 4 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients

133. Additional file 5 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients

134. Additional file 8 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients

135. Additional file 6 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients

136. Additional file 4 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients

137. Additional file 2 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients

138. Additional file 1 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients

139. Additional file 3 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients

140. Additional file 3 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients

141. Additional file 5 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients

142. Additional file 7 of Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients

144. Animal models of multiple system atrophy

145. Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up

147. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients

Catalog

Books, media, physical & digital resources